利奈唑胺治疗耐多药结核病患者相关不良事件的发生情况及预测因素 - Suppr

Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB.

作者信息

Oehadian A, Bastos M L, Centis R, D'Ambrosio L, Migliori G B, Santoso P, Ruslami R, Menzies D

机构信息

Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Hasan Sadikin General Hospital/Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; Doctoral Study Program Faculty of Medicine, Universitas Padjadjaran Bandung, West Java, Indonesia.

McGill International TB Centre Montreal Chest Institute, Research Institute of the McGill University Health Centre, Montreal, Canada; Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

出版信息

Pulmonology. 2024 Mar-Apr;30(2):184-187. doi: 10.1016/j.pulmoe.2023.09.003. Epub 2023 Oct 1.

DOI:10.1016/j.pulmoe.2023.09.003

PMID:37783640

Abstract

摘要

相似文献

Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB.

Pulmonology. 2024 Mar-Apr;30(2):184-187. doi: 10.1016/j.pulmoe.2023.09.003. Epub 2023 Oct 1.

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.

Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.

Emerg Infect Dis. 2020 Aug;26(8):1792-1800. doi: 10.3201/eid2608.191499.

Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.

BMC Infect Dis. 2017 Jun 12;17(1):417. doi: 10.1186/s12879-017-2499-1.

Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.

Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12.

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

J Antimicrob Chemother. 2010 Apr;65(4):775-83. doi: 10.1093/jac/dkq017. Epub 2010 Feb 11.

Is Severe and Long-lasting Linezolid-induced Optic Neuropathy Reversible?

Intern Med. 2018 Dec 15;57(24):3611-3613. doi: 10.2169/internalmedicine.1344-18. Epub 2018 Aug 10.

Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China.

Drug Discov Ther. 2022 May 17;16(2):96-98. doi: 10.5582/ddt.2022.01024. Epub 2022 Apr 20.

Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy.

J Basic Clin Physiol Pharmacol. 2021 Jun 25;32(4):777-781. doi: 10.1515/jbcpp-2020-0468.

Haematological adverse effects associated with linezolid in patients with drug-resistant tuberculosis: an exploratory study.

Int J Pharm Pract. 2019 Dec;27(6):575-577. doi: 10.1111/ijpp.12543. Epub 2019 May 6.

引用本文的文献

Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB.

IJTLD Open. 2025 Aug 13;2(8):450-458. doi: 10.5588/ijtldopen.25.0151. eCollection 2025 Aug.

Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study.

Precis Clin Med. 2025 Apr 18;8(2):pbaf008. doi: 10.1093/pcmedi/pbaf008. eCollection 2025 Jun.

Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis.

J Bras Pneumol. 2025 Mar 31;51(1):e20240391. doi: 10.36416/1806-3756/e20240391. eCollection 2025.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB.

作者信息

Oehadian A, Bastos M L, Centis R, D'Ambrosio L, Migliori G B, Santoso P, Ruslami R, Menzies D

机构信息

出版信息

Pulmonology. 2024 Mar-Apr;30(2):184-187. doi: 10.1016/j.pulmoe.2023.09.003. Epub 2023 Oct 1.

DOI:10.1016/j.pulmoe.2023.09.003

PMID:37783640

Abstract

摘要

相似文献

Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB.

Pulmonology. 2024 Mar-Apr;30(2):184-187. doi: 10.1016/j.pulmoe.2023.09.003. Epub 2023 Oct 1.

Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.

Emerg Infect Dis. 2020 Aug;26(8):1792-1800. doi: 10.3201/eid2608.191499.

Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.

BMC Infect Dis. 2017 Jun 12;17(1):417. doi: 10.1186/s12879-017-2499-1.

Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.

Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12.

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

J Antimicrob Chemother. 2010 Apr;65(4):775-83. doi: 10.1093/jac/dkq017. Epub 2010 Feb 11.

Is Severe and Long-lasting Linezolid-induced Optic Neuropathy Reversible?

Intern Med. 2018 Dec 15;57(24):3611-3613. doi: 10.2169/internalmedicine.1344-18. Epub 2018 Aug 10.

Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China.

Drug Discov Ther. 2022 May 17;16(2):96-98. doi: 10.5582/ddt.2022.01024. Epub 2022 Apr 20.

Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy.

J Basic Clin Physiol Pharmacol. 2021 Jun 25;32(4):777-781. doi: 10.1515/jbcpp-2020-0468.

Haematological adverse effects associated with linezolid in patients with drug-resistant tuberculosis: an exploratory study.

Int J Pharm Pract. 2019 Dec;27(6):575-577. doi: 10.1111/ijpp.12543. Epub 2019 May 6.

引用本文的文献

Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB.

IJTLD Open. 2025 Aug 13;2(8):450-458. doi: 10.5588/ijtldopen.25.0151. eCollection 2025 Aug.

Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study.

Precis Clin Med. 2025 Apr 18;8(2):pbaf008. doi: 10.1093/pcmedi/pbaf008. eCollection 2025 Jun.

Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis.

J Bras Pneumol. 2025 Mar 31;51(1):e20240391. doi: 10.36416/1806-3756/e20240391. eCollection 2025.

Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB.

作者信息

机构信息

出版信息

相似文献

引用本文的文献